Historical review uncovers the clinical evolution of cardiac amyloidosis from post-mortem fibril observation to molecular typing, highlighting milestones in targeted therapeutics.
Key Points
Trace the historical evolution of cardiac amyloidosis from early post-mortem pathological observations to contemporary diagnostic breakthroughs and targeted disease-modifying therapies.
Conducted a narrative historical review detailing the discovery, histological staining advances, and molecular subtyping of systemic and cardiac amyloidosis.
Traces the transition of amyloid from an early botanical misnomer to a recognized human pathology identified histologically via Congo red staining.
Documents the identification of specific precursor proteins responsible for light chain (AL), serum amyloid A (AA), and transthyretin (ATTR) amyloidosis subtypes.
Highlights how modern diagnostic imaging and targeted molecular therapies have transformed cardiac amyloidosis from a chronically under-recognized, fatal condition into a treatable disease.